No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
HK Stock MarketDetailed Quotes
09995 REMEGEN
- 22.500
- -0.100-0.44%
Trading Jul 3 15:50 CST
12.25BMarket Cap-7227P/E (TTM)
23.100High22.400Low1.35MVolume23.000Open22.600Pre Close30.60MTurnover0.71%Turnover RatioLossP/E (Static)544.33MShares50.30052wk High3.61P/B4.27BFloat Cap14.96052wk Low--Dividend TTM189.58MShs Float149.800Historical High--Dividend LFY3.10%Amplitude14.960Historical Low22.740Avg Price500Lot Size--Div YieldTTM--Div Yield LFY
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Remegen (09995.HK) had 536,000 shares of shareholding reduced by E Fund.
According to the latest equity disclosure information from the Stock Exchange, on June 18, 2024, Remegen (09995.HK) experienced a shareholding reduction of 536,000 shares with an average price of HKD 26.5858 per share by E Fund Management Co., Ltd., involving approximately HKD 14.25 million. After the reduction, E Fund Management Co., Ltd.'s latest shareholding decreased to 9.1615 million shares, and the shareholding ratio decreased from 5.12% to 4.83%.
We Think Some Shareholders May Hesitate To Increase RemeGen Co., Ltd.'s (HKG:9995) CEO Compensation
Key Insights RemeGen's Annual General Meeting to take place on 28th of June CEO Jianmin Fang's total compensation includes salary of CN¥5.43m The overall pay is 385% above the industry average R
Remegen (09995.HK) received 423,000 shareholdings from Norges Bank.
According to the latest equity disclosure information from the Stock Exchange, on June 17, 2024, Remegen (09995.HK) received 423,000 additional shareholdings from Norges Bank on the exchange at an average price of HKD 27.872 per share, with a total value of approximately HKD 11.79 million. After the increase, the latest number of shares held by Norges Bank has increased from 4.83% to 5.05%.
Remegen (09995) has opened a special settlement account for its fundraising financial products.
Remegen (09995) announced that the second board of directors' eleventh meeting was held on March 27, 2024 according to the announcement.
HKEX unusual market activity | Remegen (09995) rose more than 4% during trading, with clinical research on injection Vedolizumab achieving major endpoints.
According to the Zhitong Finance and Economics APP, Remegen (09995) rose more than 4% during trading and at the time of publication, rose 3.45% to HKD 27, with a turnover of HKD 18.1935 million. On June 13th, Remegen announced that the Phase III clinical study of the single-domain anti-HER2 antibody (trade name: Aidi Xi) for the treatment of HER2-positive breast cancer patients with liver metastasis achieved positive results and reached the primary research endpoint. The company plans to submit a listing application to the Drug Evaluation Center (CDE) of the National Medical Products Administration in the near future. It is reported that in 2023, Remegen's sales of injection-type vidisiclib in the pharmaceutical industry reached 17.3.
RemeGen Phase Three Breast Cancer Clinical Trial Meets Primary Endpoint; Shares Rise 3%
RemeGen (HKG:9995) met the primary endpoint of its phase three trial investigating the use of its Disitamab Vedotin for Injection for the treatment of breast cancer patients with liver metastases, acc
Comments
RemeGen's high P/S ratio, driven by current investor sentiment and future expectations, may be concerning given the company's less than stellar revenue forecasts. Unless conditions improve, these prices may not be reasonable.
RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 29% But Its Business Is Yet to Catch Up 1
Despite RemeGen's subdued revenue growth projections, it trades at a P/S ratio similar to the industry, suggesting investors may be less bearish than analysts. However, its weaker revenue outlook could risk a share price decline and pose a risk to shareholders.
1
$REMEGEN(09995.HK$ This shitty stock
$Hang Seng Index(800000.HK$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
1
In FT's story, The commerce department is expected to place more than two dozen Chinese companies on the entity list on Thursday, including some involved in biotechnology.
The news triggers the sell-off in Hong Kong.
$WUXI BIO(02269.HK$ $WUXI APPTEC(02359.HK$ $CLOVER BIO-B(02197.HK$ $REMEGEN(09995.HK$
The news triggers the sell-off in Hong Kong.
$WUXI BIO(02269.HK$ $WUXI APPTEC(02359.HK$ $CLOVER BIO-B(02197.HK$ $REMEGEN(09995.HK$
4
Read more
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg